Moderna
Cambridge, Massachusetts, United States
Brett Leav, MD is Executive Director of Clinical Development for Public Health Vaccines at Moderna, with responsibility for overseeing the Global and Public Health Vaccine portfolio. Dr. Leav joined Moderna in April 2020 and before assuming his current role, led the Moderna COVID-19 vaccine clinical program in adults and children, where he was able to contribute his deep knowledge and experience in vaccine development to address this global crisis. As Executive Director for Global and Public Health Vaccines, Dr. Leav currently oversees the clinical development of mRNA vaccines intended to prevent intractable infectious diseases and potential pandemic pathogens.
Prior to joining Moderna, Dr. Leav led clinical development of novel seasonal influenza vaccines at Seqirus (CSL) and Novartis, where his team designed and conducted clinical trials for global licensure including the FDA approval of the first adjuvanted seasonal influenza vaccine, Fluad®. Dr. Leav's interest in vaccines began during his tenure as a clinician and researcher at Tufts Medical Center, where he served as Principal Investigator of an NIH-funded research effort to understand the mucosal immune response to the enteric pathogen, Cryptosporidium parvum. He then applied his knowledge of immunology to the development and regulatory approval of monoclonal antibodies against rabies and Clostridioides difficile at MassBiologics, a non-profit, FDA-licensed manufacturer of vaccines. He is an author of more than 50 peer-reviewed publications resulting from his work.
Dr. Leav received his medical degree from the University of Massachusetts in Worcester, Massachusetts. He completed his internal medicine residency at Georgetown University Medical Center in Washington DC and his fellowship in Geographic Medicine and Infectious Diseases at Tufts Medical Center after practicing primary care internal medicine for several years in Waltham, Massachusetts. He maintains board certification in Infectious Diseases.
Disclosure information not submitted.
Monday, October 20, 2025
3:39 PM - 3:51 PM US ET